CompanyShort-termNeutralDays to weeksBenzingaMRK

Merck Receives FDA Approval For Its Dual Oral Regimen Of WELIREG Plus LENMIVA For The Treatment Of Adult Patients With Advanced Renal Cell Carcinoma With A Clear Cell Component

Reviewed by ClearTape · Source: Benzinga

Key takeaways

Merck’s WELIREG plus LENVIMA combo gets FDA clearance after showing better PFS and ORR than cabozantinib in advanced ccRCC.
Median PFS 14.6 months vs 10.6 months
HR 0.74 (95% CI 0.61‑0.89)
ORR 53% vs 40%

What happened

The U.S. Food and Drug Administration approved Merck’s dual oral regimen of WELIREG (belzutifan) plus LENVIMA (lenvatinib) for adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) who have progressed after a PD‑1 or PD‑L1 inhibitor.

Why it matters

The approval follows Phase 3 LITESPARK‑011 data showing the combination improves progression‑free survival and objective response rate versus cabozantinib, offering a new oral therapy option for a heavily pre‑treated population.

Short-term and longer-term

Short-term. Short‑term traders should watch MRK’s earnings for the first quarterly update on the new indication and monitor any price swings around the ESMO presentation.

Longer-term. Over the next 12‑18 months, MRK could see incremental revenue from the new ccRCC indication, especially if the combination captures market share from existing TKIs.

ClearTape summarizes context in-app. For the full publisher article, use Read original source above.